Coelho Yasmin Nascimento Bernardes, Soldi Luiz Ricardo, da Silva Paulo Henrique Rosa, Mesquita Caio Melo, Paranhos Luiz Renato, Dos Santos Thaísa Reis, Silva Marcelo José Barbosa
Institute of Biomedical Sciences, Federal University of Uberlândia-UFU, Uberlândia, MG, Brazil.
School of Dentistry, Federal University of Uberlândia-UFU, Uberlândia, MG, Brazil.
Front Vet Sci. 2023 Jun 8;10:1188795. doi: 10.3389/fvets.2023.1188795. eCollection 2023.
The current gold standard treatment for canine mast cell tumors (MCT) uses vinblastine sulfate (VBL) as chemotherapy, although tyrosine kinase inhibitors (TKI) have recently been shown to be worthy candidates for treatment. This systematic review aimed to analyze the overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and complete (CR) or partial response (PR) in dogs with MCT treated with TKI compared to standard VBL treatment. The systematic review was registered in the Open Science Framework (OSF) database under the identifier 10.17605/OSF.IO/WYPN4 (https://osf.io/). An electronic search was performed in nine databases. References from eligible studies were also selected to find more registers. A total of 28 studies met the eligibility criteria, and one more was recovered from the references of eligible studies, totaling 29 selected studies. The overall response rate, complete response, and partial response were higher in dogs treated with tyrosine kinase inhibitors than in dogs treated with vinblastine. The overall survival and progression-free survival of vinblastine-treated dogs were higher compared to tyrosine kinase inhibitors-treated dogs. Dogs with mutated KIT treated with tyrosine kinase inhibitors have longer overall survival and progression-free survival compared to those treated with vinblastine. It is important to consider the limitation of the study which should temper the interpretation of the results, videlicet, the extracted data lacked sample standardization and included variables such as animal characteristics, mutation detection methods, tumor characteristics, and treatment types which may have influenced the outcome of the study.
https://osf.io/, identifier: 10.17605/OSF.IO/WYPN4.
目前犬肥大细胞瘤（MCT）的金标准治疗方法是使用硫酸长春碱（VBL）进行化疗，尽管酪氨酸激酶抑制剂（TKI）最近已被证明是有价值的治疗候选药物。本系统评价旨在分析与标准VBL治疗相比，接受TKI治疗的MCT犬的总生存期（OS）、无进展生存期（PFS）、总缓解率（ORR）以及完全缓解（CR）或部分缓解（PR）情况。该系统评价已在开放科学框架（OSF）数据库中注册，标识符为10.17605/OSF.IO/WYPN4（https://osf.io/）。在九个数据库中进行了电子检索。还从符合条件的研究参考文献中筛选以找到更多记录。共有28项研究符合纳入标准，另外从符合条件研究的参考文献中又筛选出1项，总计29项入选研究。接受酪氨酸激酶抑制剂治疗的犬的总缓解率、完全缓解率和部分缓解率高于接受长春碱治疗的犬。与接受酪氨酸激酶抑制剂治疗的犬相比，接受长春碱治疗的犬的总生存期和无进展生存期更长。与接受长春碱治疗的犬相比，接受酪氨酸激酶抑制剂治疗的KIT基因发生突变的犬具有更长的总生存期和无进展生存期。重要的是要考虑到本研究的局限性，这可能会影响对结果的解释，即提取的数据缺乏样本标准化，并且包括动物特征、突变检测方法、肿瘤特征和治疗类型等变量，这些可能影响了研究结果。
